このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Mega Lifesciences 将来の成長

Future 基準チェック /26

Mega Lifesciences利益と収益がそれぞれ年間10.9%と4.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に24.8% 10.9%なると予測されています。

主要情報

11.7%

収益成長率

11.6%

EPS成長率

Pharmaceuticals 収益成長	17.1%
収益成長率	5.4%
将来の株主資本利益率	24.7%
アナリストカバレッジ	Good
最終更新日	04 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

SET:MEGA - アナリストの将来予測と過去の財務データ ( )THB Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	17,878	2,770	2,626	2,974	6
12/31/2025	16,691	2,543	2,364	2,711	7
12/31/2024	15,813	2,383	2,270	2,814	7
6/30/2024	15,685	1,999	2,400	2,667	N/A
3/31/2024	15,718	2,017	1,915	2,166	N/A
12/31/2023	15,716	1,993	1,633	1,926	N/A
9/30/2023	15,442	1,919	2,297	2,583	N/A
6/30/2023	15,693	2,042	1,773	2,035	N/A
3/31/2023	15,634	2,081	1,798	2,077	N/A
12/31/2022	15,727	2,242	1,684	1,997	N/A
9/30/2022	15,116	2,338	1,327	1,596	N/A
6/30/2022	15,061	2,292	1,852	2,091	N/A
3/31/2022	14,724	2,227	1,800	2,025	N/A
12/31/2021	14,172	1,947	2,567	2,727	N/A
9/30/2021	14,395	1,878	2,302	2,474	N/A
6/30/2021	13,775	1,607	2,289	2,485	N/A
3/31/2021	12,809	1,406	1,932	2,178	N/A
12/31/2020	12,613	1,393	1,374	1,629	N/A
9/30/2020	12,168	1,348	1,487	1,815	N/A
6/30/2020	11,642	1,288	1,122	1,508	N/A
3/31/2020	11,655	1,205	1,271	1,707	N/A
12/31/2019	11,164	1,139	954	1,495	N/A
9/30/2019	10,950	1,163	468	1,406	N/A
6/30/2019	10,712	1,136	275	1,163	N/A
3/31/2019	10,569	1,203	-158	657	N/A
12/31/2018	10,284	1,206	158	910	N/A
9/30/2018	10,147	1,183	429	747	N/A
6/30/2018	9,937	1,175	569	929	N/A
3/31/2018	9,829	1,178	N/A	1,150	N/A
12/31/2017	9,624	1,113	N/A	927	N/A
9/30/2017	9,514	1,023	N/A	967	N/A
6/30/2017	9,282	945	N/A	1,081	N/A
3/31/2017	8,968	873	N/A	1,237	N/A
12/31/2016	8,828	795	N/A	1,250	N/A
9/30/2016	8,514	771	N/A	1,174	N/A
6/30/2016	8,226	756	N/A	920	N/A
3/31/2016	8,115	703	N/A	764	N/A
12/31/2015	7,966	696	N/A	609	N/A
9/30/2015	7,775	675	N/A	825	N/A
6/30/2015	7,862	634	N/A	803	N/A
3/31/2015	7,851	598	N/A	581	N/A
12/31/2014	7,749	548	N/A	614	N/A
9/30/2014	7,620	474	N/A	406	N/A
6/30/2014	7,422	516	N/A	416	N/A
3/31/2014	7,226	567	N/A	473	N/A
12/31/2013	7,055	624	N/A	466	N/A
9/30/2013	6,812	593	N/A	380	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MEGAの予測収益成長率 (年間10.9% ) は貯蓄率 ( 1.9% ) を上回っています。

収益対市場: MEGAの収益 ( 10.9% ) TH市場 ( 14.9% ) よりも低い成長が予測されています。

高成長収益: MEGAの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: MEGAの収益 ( 4.6% ) TH市場 ( 6.6% ) よりも低い成長が予測されています。

高い収益成長: MEGAの収益 ( 4.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MEGAの自己資本利益率は、3年後には高くなると予測されています ( 24.8 %)

Mega Lifesciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘